{"id":9437,"date":"2025-04-03T07:37:05","date_gmt":"2025-04-03T07:37:05","guid":{"rendered":"https:\/\/goldenpi.com\/blog\/?p=9437"},"modified":"2026-02-25T09:01:42","modified_gmt":"2026-02-25T09:01:42","slug":"dishman-carbogen-amcis-limited","status":"publish","type":"post","link":"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/","title":{"rendered":"DISHMAN CARBOGEN AMCIS LIMITED"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_79_2 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Introduction_A_CRAMS_Powerhouse\" >Introduction: A CRAMS Powerhouse<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Financial_Overview\" >Financial Overview<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Snapshot_stating_the_Revenue_Expenses_Net_Worth_Total_Debt_and_PAT_In_crores\" >Snapshot stating the Revenue, Expenses, Net Worth, Total Debt and PAT (In crores)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Cash_flow_for_last_few_years_In_crores\" >Cash flow for last few years (In crores)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Revenue_Profitability\" >Revenue &amp; Profitability<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Business_Segments\" >Business Segments<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Capex_Growth_Investments\" >Capex &amp; Growth Investments<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Key_Strengths_of_Dishman_Carbogen_Amcis_Limited\" >Key Strengths of Dishman Carbogen Amcis Limited<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Asset-Backed_Security_for_NCD_Investors\" >Asset-Backed Security for NCD Investors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Strong_Promoter_Guarantee_Financial_Strength\" >Strong Promoter Guarantee &amp; Financial Strength<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Stable_Revenue_Growth_Improving_Profitability\" >Stable Revenue Growth &amp; Improving Profitability<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Global_CRAMS_Leader_with_Strong_Infrastructure\" >Global CRAMS Leader with Strong Infrastructure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Regulatory_Clearances_Business_Stability\" >Regulatory Clearances &amp; Business Stability<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Strong_Market_Presence_Liquidity\" >Strong Market Presence &amp; Liquidity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Geographic_Reach_Revenue_Sources\" >Geographic Reach &amp; Revenue Sources<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Key_Risks_Weaknesses\" >Key Risks &amp; Weaknesses<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#High_Debt_Levels_Leverage\" >High Debt Levels &amp; Leverage<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Margin_Pressure_Due_to_Rising_Costs\" >Margin Pressure Due to Rising Costs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Pending_Tax_Litigation_Contingent_Liability\" >Pending Tax Litigation (Contingent Liability)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Working_Capital_Challenges\" >Working Capital Challenges<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Concentration_in_Oncology\" >Concentration in Oncology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Capacity_Utilization_Still_Ramp-Up_Mode\" >Capacity Utilization Still Ramp-Up Mode<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Debt_Servicing_Ability\" >Debt Servicing Ability<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Liquidity_Position\" >Liquidity Position<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Debt_Repayment_Schedule\" >Debt Repayment Schedule<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Interest_Coverage_Ratio_ICR\" >Interest Coverage Ratio (ICR)<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Cashflow_for_1000_Dishman_Carbogen_Amcis_Limited_2027\" >Cashflow for 10.00% Dishman Carbogen Amcis Limited 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Investment_Verdict_Should_You_Invest_in_DCALs_NCDs\" >Investment Verdict: Should You Invest in DCAL\u2019s NCDs?<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#%E2%9C%85_Reasons_to_Invest\" >\u2705 Reasons to Invest<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#%E2%9A%A0%EF%B8%8F_Caution_Points\" >\u26a0\ufe0f Caution Points<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-31\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#Final_Takeaway\" >Final Takeaway<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Introduction_A_CRAMS_Powerhouse\"><\/span><b>Introduction: A CRAMS Powerhouse<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Dishman Carbogen Amcis Limited (DCAL) is a globally recognized <\/span><b>Contract Research and Manufacturing Services (CRAMS)<\/b><span style=\"font-weight: 400;\"> company with over <\/span><b>40 years of expertise<\/b><span style=\"font-weight: 400;\"> in pharmaceutical APIs, high-potent APIs, intermediates, and specialty chemicals. Headquartered in India, DCAL operates <\/span><b>25 manufacturing facilities<\/b><span style=\"font-weight: 400;\"> across <\/span><b>India, Switzerland, France, the UK, China, and the Netherlands<\/b><span style=\"font-weight: 400;\">, serving <\/span><b>250+ global clients<\/b><span style=\"font-weight: 400;\">, including Novartis, Daiichi Sankyo, and Takeda.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">DCAL is now tapping the <\/span><b>debt market<\/b><span style=\"font-weight: 400;\"> with a new issuance of <\/span><b>\u20b950 crore senior secured, rated, listed, redeemable non-convertible debentures (NCDs)<\/b><span style=\"font-weight: 400;\">, offering investors a chance to participate in a well-established yet rapidly evolving global pharma player.<\/span><\/p>\n<p><img decoding=\"async\" class=\"size-full wp-image-9447 aligncenter\" src=\"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03075013\/Screenshot-2025-04-03-124731-1.png\" alt=\"\" width=\"667\" height=\"750\" srcset=\"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03075013\/Screenshot-2025-04-03-124731-1.png 667w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03075013\/Screenshot-2025-04-03-124731-1-267x300.png 267w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03075013\/Screenshot-2025-04-03-124731-1-585x658.png 585w\" sizes=\"(max-width: 667px) 100vw, 667px\" \/><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Financial_Overview\"><\/span><b>Financial Overview<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h4><span class=\"ez-toc-section\" id=\"Snapshot_stating_the_Revenue_Expenses_Net_Worth_Total_Debt_and_PAT_In_crores\"><\/span><b>Snapshot stating the Revenue, Expenses, Net Worth, Total Debt and PAT (In crores)<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p><img decoding=\"async\" class=\"size-large wp-image-9439 aligncenter\" src=\"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073413\/Picture4-1024x523.png\" alt=\"\" width=\"1024\" height=\"523\" srcset=\"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073413\/Picture4-1024x523.png 1024w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073413\/Picture4-300x153.png 300w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073413\/Picture4-768x392.png 768w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073413\/Picture4-1536x785.png 1536w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073413\/Picture4-2048x1046.png 2048w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073413\/Picture4-1170x598.png 1170w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073413\/Picture4-1920x981.png 1920w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073413\/Picture4-585x299.png 585w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/p>\n<h4><span class=\"ez-toc-section\" id=\"Cash_flow_for_last_few_years_In_crores\"><\/span><b>Cash flow for last few years (In crores)<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p><img decoding=\"async\" class=\"size-full wp-image-9440 aligncenter\" src=\"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073437\/Screenshot-2025-04-03-120406.png\" alt=\"\" width=\"798\" height=\"435\" srcset=\"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073437\/Screenshot-2025-04-03-120406.png 798w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073437\/Screenshot-2025-04-03-120406-300x164.png 300w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073437\/Screenshot-2025-04-03-120406-768x419.png 768w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073437\/Screenshot-2025-04-03-120406-585x319.png 585w\" sizes=\"(max-width: 798px) 100vw, 798px\" \/><\/p>\n<p><span style=\"font-weight: 400;\">Cash flow refers to the movement of cash in and out of the business at a specific point in time. It represents the net balance of the cash movement.<\/span><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">*Cash flow from operating activities reflects the amount a company generates through its product of services.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">**Cash flow from investing activities reflects cash generated and spent relating to investing activities, like purchase of assets, sales of securities etc.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b><span style=\"font-weight: 400;\">***Cash flow from financing activities gives an insight into the financial stability of a company to its investors. It reflects <\/span><span style=\"font-weight: 400;\">the net flows of cash that are used to fund the company.<\/span><\/b><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"Revenue_Profitability\"><\/span><b>Revenue &amp; Profitability<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><strong>Consolidated Revenue (FY24)<\/strong>: \u20b92,616 Cr, up 8% YoY (FY23: \u20b92,413 Cr).<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><strong>EBITDA (adjusted):<\/strong> \u20b9444 Cr (FY23: \u20b9457 Cr); margin at ~17%.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><strong>Net Loss (FY24):<\/strong> \u20b9153 Cr, impacted by one-time expenses (France plant launch, SAP implementation, EDQM resolution).<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><strong>Cash Profit<\/strong> stood at \u20b9278 Cr (FY23: \u20b9309 Cr).<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"Business_Segments\"><\/span><b>Business Segments<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p><img decoding=\"async\" class=\"size-full wp-image-9441 aligncenter\" src=\"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073459\/Screenshot-2025-04-03-130312.png\" alt=\"\" width=\"623\" height=\"441\" srcset=\"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073459\/Screenshot-2025-04-03-130312.png 623w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073459\/Screenshot-2025-04-03-130312-300x212.png 300w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073459\/Screenshot-2025-04-03-130312-585x414.png 585w\" sizes=\"(max-width: 623px) 100vw, 623px\" \/><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\"><strong>CRAMS contributes<\/strong> 75% of revenue (\u20b91,954 Cr); focus on oncology, CNS, and rare diseases.<\/span><\/li>\n<li><b><span style=\"font-weight: 400;\"><strong>Other segments:<\/strong> Cholesterol\/Vit D analogues (13%), APIs &amp; intermediates (8%), Quats &amp; generics (4%).<\/span><br \/>\n<\/b><\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"Capex_Growth_Investments\"><\/span><b>Capex &amp; Growth Investments<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">\u20b91,555 Cr invested in EU expansion (FY20-FY24).<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Operationalized new injectable facility in France; expected Euro 16.5 Mn in confirmed orders in FY25.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Bavla facility received regulatory clearances from PMDA (Japan) and EDQM (Europe) in early 2024.<\/span><\/li>\n<\/ul>\n<h2><\/h2>\n<h2><span class=\"ez-toc-section\" id=\"Key_Strengths_of_Dishman_Carbogen_Amcis_Limited\"><\/span><b>Key Strengths of Dishman Carbogen Amcis Limited<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h4><span class=\"ez-toc-section\" id=\"Asset-Backed_Security_for_NCD_Investors\"><\/span><b>Asset-Backed Security for NCD Investors<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>1.1x value of immovable commercial properties<\/b><span style=\"font-weight: 400;\"> of Dishman Carbogen Amcis Ltd (\u20b910 Cr loan).<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>1.25x value of Dishman Infrastructure Ltd\u2019s industrial land<\/b><span style=\"font-weight: 400;\"> (\u20b940 Cr loan).<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>First charge on all current and fixed assets<\/b><span style=\"font-weight: 400;\"> of Dishman Infrastructure Ltd, ensuring investor protection.<\/span><\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"Strong_Promoter_Guarantee_Financial_Strength\"><\/span><b>Strong Promoter Guarantee &amp; Financial Strength<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Unconditional and irrevocable corporate guarantee<\/b><span style=\"font-weight: 400;\"> from <\/span><b>Mr. Arpit Janmejay Vyas (Global MD)<\/b><span style=\"font-weight: 400;\">, who has a <\/span><b>net worth of \u20b9755 Cr<\/b><span style=\"font-weight: 400;\"> and drew a <\/span><b>salary of \u20b98.35 Cr in FY24<\/b><span style=\"font-weight: 400;\"> from a Swiss subsidiary.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Cash Collateral of \u20b93 Cr<\/b><span style=\"font-weight: 400;\"> maintained as a <\/span><b>Debt Service Reserve Account (DSRA)<\/b><span style=\"font-weight: 400;\">, placed as an interest-free deposit ensuring liquidity for interest payments.<\/span><\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"Stable_Revenue_Growth_Improving_Profitability\"><\/span><b>Stable Revenue Growth &amp; Improving Profitability<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Consolidated revenue grew by 8% YoY<\/b><span style=\"font-weight: 400;\">, from <\/span><b>\u20b92,413 Cr in FY23 to \u20b92,616 Cr in FY24<\/b><span style=\"font-weight: 400;\">.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>EBITDA improved from \u20b9332 Cr (FY23) to \u20b9396 Cr (FY24)<\/b><span style=\"font-weight: 400;\">, despite regulatory and operational challenges.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Order book of CHF 120 Mn (\u20b91,000+ Cr)<\/b><span style=\"font-weight: 400;\">, with expected inflows of <\/span><b>CHF 18-20 Mn (\u20b9150-160 Cr) into India over the next 2-3 years<\/b><span style=\"font-weight: 400;\">.<\/span><\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"Global_CRAMS_Leader_with_Strong_Infrastructure\"><\/span><b>Global CRAMS Leader with Strong Infrastructure<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>25 manufacturing facilities &amp; 28 R&amp;D labs<\/b><span style=\"font-weight: 400;\"> across <\/span><b>6 countries<\/b><span style=\"font-weight: 400;\">, approved by <\/span><b>USFDA, EDQM, PMDA, Swiss Medic, and WHO<\/b><span style=\"font-weight: 400;\">.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>40+ years of experience<\/b><span style=\"font-weight: 400;\"> in CRAMS, APIs, and specialty chemicals.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>2,200+ employees, 950+ scientists in R&amp;D<\/b><span style=\"font-weight: 400;\">, with <\/span><b>50% holding Ph.D. degrees<\/b><span style=\"font-weight: 400;\">, ensuring innovation-driven growth.<\/span><\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"Regulatory_Clearances_Business_Stability\"><\/span><b>Regulatory Clearances &amp; Business Stability<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Bavla (India) facility cleared EDQM &amp; PMDA audits (Jan &amp; Feb 2024)<\/b><span style=\"font-weight: 400;\">, enabling new business from Europe.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>No customer loss despite regulatory hurdles<\/b><span style=\"font-weight: 400;\">, demonstrating <\/span><b>high client stickiness<\/b><span style=\"font-weight: 400;\"> (switching suppliers takes <\/span><b>24-36 months<\/b><span style=\"font-weight: 400;\">).<\/span><\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"Strong_Market_Presence_Liquidity\"><\/span><b>Strong Market Presence &amp; Liquidity<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Listed on NSE &amp; BSE<\/b><span style=\"font-weight: 400;\"> with a <\/span><b>market cap of \u20b94,231 Cr (Dec 2024)<\/b><span style=\"font-weight: 400;\">.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>95% revenue from exports<\/b><span style=\"font-weight: 400;\">, primarily from <\/span><b>Europe (major share) and the US<\/b><span style=\"font-weight: 400;\">.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Cash &amp; equivalents: \u20b9392 Cr (1H25)<\/b><span style=\"font-weight: 400;\">, supporting short-term obligations.<\/span><\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"Geographic_Reach_Revenue_Sources\"><\/span><b> Geographic Reach &amp; Revenue Sources<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Over <\/span><b>95% revenue from exports<\/b><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Major markets:<\/b><span style=\"font-weight: 400;\"> Europe, US, Japan<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>CHF 120 Mn<\/b><span style=\"font-weight: 400;\"> order book (Dec 2024), a testament to long-term CRAMS demand<\/span><\/li>\n<\/ul>\n<h2><\/h2>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_Weaknesses\"><\/span><b>Key Risks &amp; Weaknesses<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h4><span class=\"ez-toc-section\" id=\"High_Debt_Levels_Leverage\"><\/span><b>High Debt Levels &amp; Leverage<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Consolidated Net Debt\/EBITDA at 5.9x (FY24)<\/b><span style=\"font-weight: 400;\">, indicating elevated leverage.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Short-term borrowings (\u20b9923 Cr in 1H25)<\/b><span style=\"font-weight: 400;\"> could pressure liquidity if EBITDA growth slows.<\/span><\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"Margin_Pressure_Due_to_Rising_Costs\"><\/span><b>Margin Pressure Due to Rising Costs<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>EBITDA margin declined to 17% in FY24 (vs. 19% in FY22)<\/b><span style=\"font-weight: 400;\"> due to:<\/span>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Higher raw material costs.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">One-time expenses (SAP implementation, EDQM compliance).<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Initial losses from <\/span><b>new French injectable facility (\u20b946 Cr impact in FY24)<\/b><span style=\"font-weight: 400;\">.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"Pending_Tax_Litigation_Contingent_Liability\"><\/span><b>Pending Tax Litigation (Contingent Liability)<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Income tax demand of \u20b9346 Cr<\/b><span style=\"font-weight: 400;\"> (\u20b9180 Cr related to goodwill amortization dispute).<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>\u20b956 Cr paid under protest<\/b><span style=\"font-weight: 400;\">; appeal filed with CIT\/ITAT.<\/span><\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"Working_Capital_Challenges\"><\/span><b>Working Capital Challenges<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Long working capital cycle (~390 days)<\/b><span style=\"font-weight: 400;\"> due to:<\/span>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><b>Raw material lead time (75-120 days)<\/b><span style=\"font-weight: 400;\">.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><b>Manufacturing &amp; shipping delays (270-300 days)<\/b><span style=\"font-weight: 400;\">.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><b>Customer credit period (75-120 days)<\/b><span style=\"font-weight: 400;\">.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"Concentration_in_Oncology\"><\/span><b> Concentration in Oncology<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">~50% of CRAMS revenue is oncology-focused, exposing the business to therapeutic segment-specific risks<\/span><\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"Capacity_Utilization_Still_Ramp-Up_Mode\"><\/span><b><\/b> <b>Capacity Utilization Still Ramp-Up Mode<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Indian facilities:<\/span>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Bavla: <strong>50% utilization (FY24)<\/strong><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Naroda: Dropped from 85% (FY23) to <\/span><b>70% in FY24<\/b><\/li>\n<\/ul>\n<\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Some overseas facilities (e.g. Shanghai) remain underutilized (35%)<\/span><\/li>\n<\/ul>\n<h2><\/h2>\n<h2><span class=\"ez-toc-section\" id=\"Debt_Servicing_Ability\"><\/span><b>Debt Servicing Ability<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h4><span class=\"ez-toc-section\" id=\"Liquidity_Position\"><\/span><b>Liquidity Position<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Cash &amp; equivalents: \u20b9392 Cr (1H25)<\/b><span style=\"font-weight: 400;\">.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>DSRA of \u20b93 Cr<\/b><span style=\"font-weight: 400;\"> ensures <\/span><b>interest payment security<\/b><span style=\"font-weight: 400;\">.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Short-term debt: \u20b9923 Cr (1H25)<\/b><span style=\"font-weight: 400;\"> vs. <\/span><b>operating cash flow of \u20b959 Cr (1H25)<\/b><span style=\"font-weight: 400;\"> \u2013 needs monitoring.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Listed on NSE &amp; BSE, with public holding of <\/span><b>40.68%<\/b><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Business is cash-generating with strong export receivables; however, working capital cycles remain elongated due to the nature of CRAMS operations<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Expected cash inflow<\/b><span style=\"font-weight: 400;\"> of INR 150-160 Cr to standalone entity over 2\u20133 years from the CHF 120 Mn orderbook<\/span><\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"Debt_Repayment_Schedule\"><\/span><b>Debt Repayment Schedule<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Major repayments due in FY26 (\u20b9258 Cr) &amp; FY27 (\u20b9974 Cr)<\/b><span style=\"font-weight: 400;\">.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Bullet repayment of CHF 100 Mn (\u20b9913 Cr) in FY27<\/b><span style=\"font-weight: 400;\"> (Swiss loan).<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Market-linked debentures (\u20b958 Cr) due in FY26<\/b><span style=\"font-weight: 400;\"> \u2013 refinancing risk exists.<\/span><\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"Interest_Coverage_Ratio_ICR\"><\/span><b>Interest Coverage Ratio (ICR)<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>ICR at 2.6x (1H25)<\/b><span style=\"font-weight: 400;\">, down from <\/span><b>6.6x in FY21<\/b><span style=\"font-weight: 400;\">, but still manageable.<\/span><\/li>\n<\/ul>\n<h2><\/h2>\n<h2><span class=\"ez-toc-section\" id=\"Cashflow_for_1000_Dishman_Carbogen_Amcis_Limited_2027\"><\/span><b>Cashflow for 10.00% Dishman Carbogen Amcis Limited 2027<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><img decoding=\"async\" class=\"size-large wp-image-9442 aligncenter\" src=\"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073539\/Picture5-1024x384.png\" alt=\"\" width=\"1024\" height=\"384\" srcset=\"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073539\/Picture5-1024x384.png 1024w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073539\/Picture5-300x112.png 300w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073539\/Picture5-768x288.png 768w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073539\/Picture5-1536x576.png 1536w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073539\/Picture5-2048x768.png 2048w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073539\/Picture5-1170x439.png 1170w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073539\/Picture5-1920x720.png 1920w, https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/03073539\/Picture5-585x219.png 585w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Investment_Verdict_Should_You_Invest_in_DCALs_NCDs\"><\/span><b>Investment Verdict: Should You Invest in DCAL\u2019s NCDs?<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h4><span class=\"ez-toc-section\" id=\"%E2%9C%85_Reasons_to_Invest\"><\/span><b>\u2705 Reasons to Invest<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p><span style=\"font-weight: 400;\">\u2714 <\/span><b>Secured NCDs<\/b><span style=\"font-weight: 400;\"> backed by real estate &amp; promoter guarantee.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><span style=\"font-weight: 400;\">\u2714 <\/span><b>Stable revenue growth (8% YoY) &amp; improving EBITDA<\/b><span style=\"font-weight: 400;\">.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><span style=\"font-weight: 400;\">\u2714 <\/span><b>Strong global CRAMS business with high entry barriers<\/b><span style=\"font-weight: 400;\">.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><span style=\"font-weight: 400;\">\u2714 <\/span><b>Regulatory clearances (EDQM, PMDA) to drive future orders<\/b><span style=\"font-weight: 400;\">.<\/span><\/p>\n<h4><span class=\"ez-toc-section\" id=\"%E2%9A%A0%EF%B8%8F_Caution_Points\"><\/span><b>\u26a0\ufe0f Caution Points<\/b><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>High leverage (Net Debt\/EBITDA at 5.9x)<\/b><span style=\"font-weight: 400;\">.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Working capital delays &amp; tax litigation risks<\/b><span style=\"font-weight: 400;\">.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>FY26-27 debt repayments need refinancing\/strong cash flows<\/b><span style=\"font-weight: 400;\">.<\/span><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Final_Takeaway\"><\/span><b>Final Takeaway<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">DCAL\u2019s NCDs offer a <\/span><b>moderate-risk, asset-backed investment<\/b><span style=\"font-weight: 400;\"> with <\/span><b>stable cash flows<\/b><span style=\"font-weight: 400;\"> from a <\/span><b>globally diversified CRAMS player<\/b><span style=\"font-weight: 400;\">. However, investors must monitor <\/span><b>debt repayment schedules, margin recovery, and regulatory risks<\/b><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For <\/span><b>risk-averse investors<\/b><span style=\"font-weight: 400;\">, the <\/span><b>asset security and promoter guarantee<\/b><span style=\"font-weight: 400;\"> provide comfort, while <\/span><b>aggressive investors<\/b><span style=\"font-weight: 400;\"> may look for <\/span><b>higher yields<\/b><span style=\"font-weight: 400;\"> if DCAL\u2019s growth trajectory improves.<\/span><\/p>\n<p><b>Disclaimer:<\/b><span style=\"font-weight: 400;\"> This is not investment advice. Conduct your own due diligence before investing.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Introduction: A CRAMS Powerhouse Dishman Carbogen Amcis Limited (DCAL) is a globally recognized Contract Research and Manufacturing Services (CRAMS) company with over&hellip;<\/p>\n","protected":false},"author":4,"featured_media":12082,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"no","_lmt_disable":"","footnotes":""},"categories":[26],"tags":[],"class_list":["post-9437","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investment-guide"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>DISHMAN CARBOGEN AMCIS LIMITED - GoldenPi | Blogs<\/title>\n<meta name=\"description\" content=\"DISHMAN CARBOGEN AMCIS LIMITED\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DISHMAN CARBOGEN AMCIS LIMITED - GoldenPi | Blogs\" \/>\n<meta property=\"og:description\" content=\"DISHMAN CARBOGEN AMCIS LIMITED\" \/>\n<meta property=\"og:url\" content=\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/\" \/>\n<meta property=\"og:site_name\" content=\"GoldenPi | Blogs\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/goldenpitech\" \/>\n<meta property=\"article:author\" content=\"goldenpitech\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-03T07:37:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-25T09:01:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/25090135\/dishman-carbogen-amcis-ltd-overview.png\" \/>\n\t<meta property=\"og:image:width\" content=\"731\" \/>\n\t<meta property=\"og:image:height\" content=\"347\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Abhijit Roy, CEO &amp; CO-Founder - GoldenPi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@GoldenPiTech\" \/>\n<meta name=\"twitter:site\" content=\"@GoldenPiTech\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Abhijit Roy, CEO &amp; CO-Founder - GoldenPi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/\",\"url\":\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/\",\"name\":\"DISHMAN CARBOGEN AMCIS LIMITED - GoldenPi | Blogs\",\"isPartOf\":{\"@id\":\"https:\/\/goldenpi.com\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/25090135\/dishman-carbogen-amcis-ltd-overview.png\",\"datePublished\":\"2025-04-03T07:37:05+00:00\",\"dateModified\":\"2026-02-25T09:01:42+00:00\",\"author\":{\"@id\":\"https:\/\/goldenpi.com\/blog\/#\/schema\/person\/7b7afc706617dbf29357675946045722\"},\"description\":\"DISHMAN CARBOGEN AMCIS LIMITED\",\"breadcrumb\":{\"@id\":\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#primaryimage\",\"url\":\"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/25090135\/dishman-carbogen-amcis-ltd-overview.png\",\"contentUrl\":\"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/25090135\/dishman-carbogen-amcis-ltd-overview.png\",\"width\":731,\"height\":347,\"caption\":\"dishman carbogen amcis ltd overview\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/goldenpi.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DISHMAN CARBOGEN AMCIS LIMITED\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/goldenpi.com\/blog\/#website\",\"url\":\"https:\/\/goldenpi.com\/blog\/\",\"name\":\"GoldenPi | Blogs\",\"description\":\"All about bonds online in India\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/goldenpi.com\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/goldenpi.com\/blog\/#\/schema\/person\/7b7afc706617dbf29357675946045722\",\"name\":\"Abhijit Roy, CEO &amp; CO-Founder - GoldenPi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/goldenpi.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/753eff78609551874c9773d3bee5eeab7bba3aa40f99a8b2405592eed9d9df89?s=96&d=https%3A%2F%2Fd2zny4996dl67j.cloudfront.net%2Fblogs%2Fwp-content%2Fuploads%2F2026%2F01%2F12111941%2FAbhijit-512x512-1-1-150x150.png&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/753eff78609551874c9773d3bee5eeab7bba3aa40f99a8b2405592eed9d9df89?s=96&d=https%3A%2F%2Fd2zny4996dl67j.cloudfront.net%2Fblogs%2Fwp-content%2Fuploads%2F2026%2F01%2F12111941%2FAbhijit-512x512-1-1-150x150.png&r=g\",\"caption\":\"Abhijit Roy, CEO &amp; CO-Founder - GoldenPi\"},\"description\":\"With over 15 years of experience across fixed income and debt markets, he brings deep domain expertise along with a strong focus on investor education and transparency. An alumnus of IIT Kharagpur and IIM Calcutta, his views are personal and should not be considered investment advice.\",\"sameAs\":[\"goldenpitech\",\"https:\/\/www.linkedin.com\/company\/goldenpi\/\",\"https:\/\/x.com\/GoldenPiTech\"],\"url\":\"https:\/\/goldenpi.com\/blog\/author\/goldenpi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DISHMAN CARBOGEN AMCIS LIMITED - GoldenPi | Blogs","description":"DISHMAN CARBOGEN AMCIS LIMITED","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/","og_locale":"en_US","og_type":"article","og_title":"DISHMAN CARBOGEN AMCIS LIMITED - GoldenPi | Blogs","og_description":"DISHMAN CARBOGEN AMCIS LIMITED","og_url":"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/","og_site_name":"GoldenPi | Blogs","article_publisher":"https:\/\/www.facebook.com\/goldenpitech","article_author":"goldenpitech","article_published_time":"2025-04-03T07:37:05+00:00","article_modified_time":"2026-02-25T09:01:42+00:00","og_image":[{"width":731,"height":347,"url":"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/25090135\/dishman-carbogen-amcis-ltd-overview.png","type":"image\/png"}],"author":"Abhijit Roy, CEO &amp; CO-Founder - GoldenPi","twitter_card":"summary_large_image","twitter_creator":"@GoldenPiTech","twitter_site":"@GoldenPiTech","twitter_misc":{"Written by":"Abhijit Roy, CEO &amp; CO-Founder - GoldenPi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/","url":"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/","name":"DISHMAN CARBOGEN AMCIS LIMITED - GoldenPi | Blogs","isPartOf":{"@id":"https:\/\/goldenpi.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#primaryimage"},"image":{"@id":"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#primaryimage"},"thumbnailUrl":"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/25090135\/dishman-carbogen-amcis-ltd-overview.png","datePublished":"2025-04-03T07:37:05+00:00","dateModified":"2026-02-25T09:01:42+00:00","author":{"@id":"https:\/\/goldenpi.com\/blog\/#\/schema\/person\/7b7afc706617dbf29357675946045722"},"description":"DISHMAN CARBOGEN AMCIS LIMITED","breadcrumb":{"@id":"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#primaryimage","url":"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/25090135\/dishman-carbogen-amcis-ltd-overview.png","contentUrl":"https:\/\/d2zny4996dl67j.cloudfront.net\/blogs\/wp-content\/uploads\/2025\/04\/25090135\/dishman-carbogen-amcis-ltd-overview.png","width":731,"height":347,"caption":"dishman carbogen amcis ltd overview"},{"@type":"BreadcrumbList","@id":"https:\/\/goldenpi.com\/blog\/investment-guide\/dishman-carbogen-amcis-limited\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/goldenpi.com\/blog\/"},{"@type":"ListItem","position":2,"name":"DISHMAN CARBOGEN AMCIS LIMITED"}]},{"@type":"WebSite","@id":"https:\/\/goldenpi.com\/blog\/#website","url":"https:\/\/goldenpi.com\/blog\/","name":"GoldenPi | Blogs","description":"All about bonds online in India","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/goldenpi.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/goldenpi.com\/blog\/#\/schema\/person\/7b7afc706617dbf29357675946045722","name":"Abhijit Roy, CEO &amp; CO-Founder - GoldenPi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/goldenpi.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/753eff78609551874c9773d3bee5eeab7bba3aa40f99a8b2405592eed9d9df89?s=96&d=https%3A%2F%2Fd2zny4996dl67j.cloudfront.net%2Fblogs%2Fwp-content%2Fuploads%2F2026%2F01%2F12111941%2FAbhijit-512x512-1-1-150x150.png&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/753eff78609551874c9773d3bee5eeab7bba3aa40f99a8b2405592eed9d9df89?s=96&d=https%3A%2F%2Fd2zny4996dl67j.cloudfront.net%2Fblogs%2Fwp-content%2Fuploads%2F2026%2F01%2F12111941%2FAbhijit-512x512-1-1-150x150.png&r=g","caption":"Abhijit Roy, CEO &amp; CO-Founder - GoldenPi"},"description":"With over 15 years of experience across fixed income and debt markets, he brings deep domain expertise along with a strong focus on investor education and transparency. An alumnus of IIT Kharagpur and IIM Calcutta, his views are personal and should not be considered investment advice.","sameAs":["goldenpitech","https:\/\/www.linkedin.com\/company\/goldenpi\/","https:\/\/x.com\/GoldenPiTech"],"url":"https:\/\/goldenpi.com\/blog\/author\/goldenpi\/"}]}},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/goldenpi.com\/blog\/wp-json\/wp\/v2\/posts\/9437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/goldenpi.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/goldenpi.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/goldenpi.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/goldenpi.com\/blog\/wp-json\/wp\/v2\/comments?post=9437"}],"version-history":[{"count":6,"href":"https:\/\/goldenpi.com\/blog\/wp-json\/wp\/v2\/posts\/9437\/revisions"}],"predecessor-version":[{"id":10151,"href":"https:\/\/goldenpi.com\/blog\/wp-json\/wp\/v2\/posts\/9437\/revisions\/10151"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/goldenpi.com\/blog\/wp-json\/wp\/v2\/media\/12082"}],"wp:attachment":[{"href":"https:\/\/goldenpi.com\/blog\/wp-json\/wp\/v2\/media?parent=9437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/goldenpi.com\/blog\/wp-json\/wp\/v2\/categories?post=9437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/goldenpi.com\/blog\/wp-json\/wp\/v2\/tags?post=9437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}